Venously and abdominally giving paclitaxel and cisplatin in treatment of advanced ovarian cancer

Abstract

Objective To summarize the clinical effect of venously and abdominally giving paclitaxel combining cisplatin in treatment of advanced ovarian cancer. Methods 72 patients with advanced ovarian cancer treated at our hospital from January, 2014 to December, 2014 were selected as the study objects and were divided into a dual-way group and a routine group according to the different methods of drug delivery. The routine group were venously given paclitaxel and cisplatin and the dual-way group venously and abdominally. The treatment effect and 3-year survival rate were compared between these two groups. Results The tumor change, ascites control, CA125, and treatment efficacy were better in the dual-way group than in the routine group, with statistical differences (all P<0.05). The patients were followed up to December, 2016 and the 3-year survival rate was 50.0% in the dual-way group and was 27.8% in the routine group, with a statistical difference (Log-rank=4.278,P=0.039). Conclusion Venously and abdominally giving paclitaxel and cisplatin in the treatment of patients with advanced ovarian cancer is effective and can effectively control ascites, shrink the tumor diameter, and effectively improve the patients’ prognosis. Key words: Paclitaxel; Cisplatin; Dual-way therapy; Advanced ovarian cancer; Clinical efficacy